128 related articles for article (PubMed ID: 22044720)
1. KHA-CARI guideline: biochemical and haematological targets: haemoglobin concentrations in patients using erythropoietin-stimulating agents.
McMahon LP; MacGinley R;
Nephrology (Carlton); 2012 Jan; 17(1):17-9. PubMed ID: 22044720
[No Abstract] [Full Text] [Related]
2. The CARI guidelines. Biochemical and haematological targets. Haemoglobin.
McMahon L;
Nephrology (Carlton); 2008 Jul; 13 Suppl 2():S44-56. PubMed ID: 18713123
[No Abstract] [Full Text] [Related]
3. Human recombinant erythropoietin in the treatment of anaemia in chronic haemodialysis patients.
Sulková S; Kvasnicka J; Kasl M; Kozlová J; Podrouzek P; Bartûsková J; Válek A
Czech Med; 1990; 13(2-3):98-106. PubMed ID: 2245762
[TBL] [Abstract][Full Text] [Related]
4. The KDIGO anemia guideline: can reason triumph over regulation?
Wish JB
Nephrol News Issues; 2012 Dec; 26(13):20, 22-3. PubMed ID: 23346853
[No Abstract] [Full Text] [Related]
5. [What are the aims and targets of renal anemia therapy?].
Eckardt KU
Dtsch Med Wochenschr; 2007 Sep; 132(36):1837-41. PubMed ID: 17726657
[No Abstract] [Full Text] [Related]
6. Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: con.
Himmelfarb J; Szczech LA
J Am Soc Nephrol; 2009 Jul; 20(7):1441-3. PubMed ID: 19579287
[No Abstract] [Full Text] [Related]
7. The clinical effects of recombinant human erythropoietin for the treatment of anemia in end stage renal disease patients on dialysis.
Uthayanaka Y; Jirajan B; Krairithichai U; Jantavanich N
Southeast Asian J Trop Med Public Health; 1993 Sep; 24(3):577-82. PubMed ID: 8160072
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials.
Sobota JT
Contrib Nephrol; 1989; 76():166-78; discussion 212-8. PubMed ID: 2684519
[No Abstract] [Full Text] [Related]
9. [Treatment of anemia in patients on a regular dialysis program using human recombinant erythropoietin].
Sulková S; Kvasnicka J; Kasl M; Kozlová J; Podrouzek P; Bartůnková J; Válek A
Cas Lek Cesk; 1989 Sep; 128(40):1257-60. PubMed ID: 2582471
[TBL] [Abstract][Full Text] [Related]
10. [Human recombinant erythropoietin (rH-EPO) in chronic hemodialysis patients].
Jalil R; Vaccarezza A; Jara A; Lira P; Vial S; Serrano V
Rev Med Chil; 1990 Jun; 118(6):629-34. PubMed ID: 1775783
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of anemia in chronically dialyzed patients].
Moynot A
Nephrologie; 1998; 19(3):125-7. PubMed ID: 9633055
[No Abstract] [Full Text] [Related]
12. [Hemoglobin targets in anemic patients with chronic kidney disease treated with erythropoietin].
Baglin A; Hanslik T; Prinseau J; Moulonguet-Doleris L
Rev Med Interne; 2008 Oct; 29(10):846-51. PubMed ID: 18054410
[TBL] [Abstract][Full Text] [Related]
13. [Renal anemia treatment and outcome of patients with chronic kidney disease].
Kuragano T; Nakanishi T
Nihon Jinzo Gakkai Shi; 2009; 51(7):852-6. PubMed ID: 19928557
[No Abstract] [Full Text] [Related]
14. Evidence and implications of haemoglobin cycling in anaemia management.
Fishbane S; Berns JS
Nephrol Dial Transplant; 2007 Aug; 22(8):2129-32. PubMed ID: 17595177
[No Abstract] [Full Text] [Related]
15. [Human recombinant erythropoietin in the treatment of anemia in patients on long-term hemodialysis].
Boratyńska M; Szewczyk Z; Szepietowski T; Czyz W; Cybulski K; Bogucki J; Szczepański J
Przegl Lek; 1990; 47(11):741-5. PubMed ID: 2098840
[TBL] [Abstract][Full Text] [Related]
16. [Erythropoietin--the first hematologic hormone in clinical use].
Rhyner K
Schweiz Med Wochenschr; 1988 Mar; 118(11):375-80. PubMed ID: 3287601
[TBL] [Abstract][Full Text] [Related]
17. [Regarding the optimal hemoglobin target range in renal anemia].
Maurin N
Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
[TBL] [Abstract][Full Text] [Related]
18. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target.
KDOQI
Am J Kidney Dis; 2007 Sep; 50(3):471-530. PubMed ID: 17720528
[No Abstract] [Full Text] [Related]
19. Erythropoietin stimulating agents and epoetin alfa revisited: what's really relevant?
Walker RG
Clin J Am Soc Nephrol; 2008 Jul; 3(4):935-7. PubMed ID: 18579671
[No Abstract] [Full Text] [Related]
20. Decreased need for blood transfusion during one year after discontinued erythropoietin treatment in haemodialyzed patients.
Kokot F; Wiecek A; Grzeszczak W
Nephron; 1991; 58(2):246-7. PubMed ID: 1865988
[No Abstract] [Full Text] [Related]
[Next] [New Search]
